Epicardial, visceral and subcutaneous adipose tissue in heart failure with preserved ejection fraction
- PMID: 40827329
- PMCID: PMC12450799
- DOI: 10.1002/ehf2.15396
Epicardial, visceral and subcutaneous adipose tissue in heart failure with preserved ejection fraction
Abstract
Aims: Obesity is common in patients with heart failure with preserved ejection fraction (HFpEF), and adipose tissue (AT) plays a key role in its pathophysiology. We examined the distribution and association of visceral AT (VAT), subcutaneous AT (SAT) and epicardial AT (EAT) in HFpEF using multimodality imaging.
Methods: Heart failure patients with left ventricular ejection fraction >40% were prospectively enrolled. All patients underwent cardiac magnetic resonance (CMR) imaging and total body computed tomography (CT). EAT was measured on CMR, and VAT, SAT and waist circumference (WC) were measured on CT. Linear regression analysis was used to assess associations between EAT and other AT depots.
Results: In total, 68 patients were included. Mean age was 73 ± 8 years; 34 (50%) were women. Twenty-six patients (38%) were obese, while 60 (91%) had increased WC and 58 (85%) had increased VAT. Body mass index (BMI) and WC were comparable between men and women, but men had more EAT (217 vs. 180 mL, P < 0.001) and VAT (306 vs. 196 cm2, P < 0.001), but less SAT (177 vs. 276 cm2, P < 0.001), as compared with women. After adjusting for age, gender and BMI, VAT was only associated with EAT, albeit modest (β = 0.40, P < 0.001, R2 = 0.40), but not with SAT.
Conclusions: The distribution of various AT depots is markedly different between men and women with HFpEF. Men have more VAT and EAT, but less SAT. The observed variation in AT depots may potentially contribute to gender-related differences in cardiovascular risk.
Keywords: AI‐assisted software; HFpEF; epicardial adipose tissue; multimodality imaging; obesity; subcutaneous adipose tissue; visceral adipose tissue.
© 2025 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
T. M. G. is supported by the Mandema‐Stipend of the Junior Scientific Masterclass 2020‐10 of the University Medical Centre Groningen. M. R. reports unrestricted grants from ZonMW, the Dutch Heart Foundation; DECISION project 848090001, the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; EmbRACE (01‐002‐2022‐0118), RACE V (CVON 2014–9), RED‐CVD (CVON2017‐11); the Top Sector Life Sciences & Health to the Dutch Heart Foundation PPP Allowance; CVON‐AI (2018B017); and European Union's Horizon 2020 research and innovation program (EHRA‐PATHS 945260). The UMCG, which employs M. R., has received consultancy fees from Bayer and InCarda Therapeutics. All the other authors have nothing to disclose.
Figures
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
